WatersFRA:WAZ +6.44%92 Net Margin % is -5.68% as of Mar. 2026. GuruFocus rates FRA:WAZ with a GF Score™ of 92/100 and a GF Value™ of €372.27 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Waters ranks better than 82.35% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Waters's Net Income for the
three
months ended in Mar. 2026 was €-62 Mil. Waters's Revenue for the
three
months ended in Mar. 2026 was €1,096 Mil. Therefore, Waters's net margin for the quarter that ended in Mar. 2026 was -5.68%.
The historical rank and industry rank for Waters's Net Margin % or its related term are showing as below:
FRA:WAZ'
s Net Margin % Range Over the Past 10 Years
Min: 0.88 Med: 22.93 Max: 24.87
Current: 11.92
FRA:WAZ's Net Margin % is ranked better than 82.35% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs FRA:WAZ: 11.92
Waters (FRA:WAZ) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Waters Net Margin % Related Terms
Waters Net Margin % Historical Data
* Premium members only.
The historical data trend for Waters's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Waters's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waters Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Waters's Net Margin % distribution charts can be found below:
* The bar in red indicates where Waters's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waters (FRA:WAZ) has a Net Margin % of -5.68% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Waters and its competitors. Over the past decade, Waters' Net Margin % has ranged from 0.88 to 24.87. According to the industry distribution chart, Waters ranks #36 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 17.6%.
Is Waters' Net Margin % too high?
Waters' current Net Margin % is -5.68%. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 24.87. Based on the distribution chart, Waters ranks #36 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Waters has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Waters' Net Margin % compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, Waters ranks #36 out of 204 companies for Net Margin %. This places Waters in the top 18% of its industry — outperforming the majority of peers. Historically, Waters' own Net Margin % has ranged from 0.88 to 24.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Waters and its competitors. Waters's current Net Margin % is -5.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Waters stock overvalued right now?
Based on GuruFocus' analysis, Waters (FRA:WAZ) is currently considered Modestly Undervalued. The stock's GF Value™ is €372.27, compared to a current price of €330.40 — trading 11.2% below its estimated fair value. The current Net Margin % is -5.68%. Waters' overall GF Score™ is 92/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Waters (FRA:WAZ), the current Net Margin % is -5.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Waters (FRA:WAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Waters stock appears to be undervalued.
The current stock price of €330.40 is trading 11.2% below its estimated GF Value™ of €372.27.
GuruFocus considers Waters to be Modestly Undervalued.
Key valuation signals for FRA:WAZ:
Net Margin %: -5.68%
GF Value™: €372.27 vs. price of €330.40 (11.2% below fair value)
No single metric tells the full story. See the FRA:WAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
92GF Score
Get the complete analysis for FRA:WAZ
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WAZ has been successfully added to your 
